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Abstract
Respiratory infections remain a major threat to cystic ﬁbrosis (CF) patients. The detection and correct identiﬁcation of the bacteria
implicated in these infections is critical for the therapeutic management of patients. The traditional methods of culture and phenotypic
identiﬁcation of bacteria lack both sensitivity and speciﬁcity because many bacteria can be missed and/or misidentiﬁed. Molecular analy-
ses have recently emerged as useful means to resolve these problems, including molecular methods for accurate identiﬁcation or detec-
tion of bacteria and molecular methods for evaluation of microbial diversity. These recent molecular technologies have increased the
list of new and/or emerging pathogens and epidemic strains associated with CF patients. Matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry of intact cells has also emerged recently as a powerful and rapid method for the routine identiﬁcation
of bacteria in clinical microbiology laboratories and will certainly represent the method of choice also for the routine identiﬁcation of
bacteria in the context of CF. Finally, recent data derived from molecular culture-independent analyses indicate the presence of a previ-
ously underestimated, complex microbial community in sputa from CF patients. Interestingly, full genome sequencing of some bacteria
frequently recovered from CF patients has highlighted the fact that the lungs of CF patients are hotspots for lateral gene transfer and
the adaptation of these ecosystems to a speciﬁc chronic condition.
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Introduction
Cystic ﬁbrosis (CF), the most common hereditary disease in
Caucasian populations, results from mutations in the CF
transmembrane conductance regulator (CFTR) gene and
affects the function of almost all of the body’s exocrine
glands [1]. It is characterized by the production of abnor-
mally viscous mucus by the affected glands, resulting mainly
in impaired respiratory and pancreatic function. Respiratory
infections, which start at an early age in the majority of peo-
ple with CF, and airway inﬂammation represent the most
serious threats during the disease, leading to pulmonary
deterioration and respiratory failure. Finally, the high morbid-
ity and mortality described in these subjects are the conse-
quence of recurrent respiratory infections [2]. Therefore,
the isolation and proper identiﬁcation of CF pathogens are
critical steps that have signiﬁcant impact on antimicrobial
treatment, patient management, cross-infection prevention
and control in CF care units, as well as on the quality of life
in these patients. The mechanisms by which the early acquisi-
tion of infection in CF patients occurs, especially in the case
of Pseudomonas aeruginosa infection, were recently reviewed
and include several hypotheses: low airway surface liquid
leading to impaired mucociliary clearance, increased availabil-
ity of cell surface receptors, reduced ingestion of bacteria by
epithelial cells and/or low levels of molecules such as nitric
oxide and antioxidant glutathione [3]. Although a few typical
bacteria are traditionally involved in CF lung infections,
including Staphylococcus aureus, P. aeruginosa, Haemophilus
inﬂuenzae and Streptococcus pneumoniae, patients with CF are
susceptible to infection by other opportunistic bacterial spe-
cies that are not usually pathogenic for healthy individuals
[4], such as members of the Burkholderia cepacia complex,
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Stenotrophomonas maltophilia, Achromobacter xylosoxidans, Pan-
doraea spp., Ralstonia spp., Inquilinus limosus, nontuberculous
mycobacteria and other species [2,5–7]. The majority of
these microbes are Gram-negative rods, environmental, mul-
tidrug resistant bacteria, and they persist, in spite of aggres-
sive and prolonged courses of antibiotic treatment, in the
patient’s lung after bioﬁlm formation. Thus, the infections
become chronic with several exacerbation episodes per year.
Accurate identiﬁcation of the bacteria involved is an impor-
tant step for understanding both the epidemiology and the
clinical implications of emerging pathogens in the CF popula-
tion. Recently, new molecular tools have led to an increase
in the number of bacteria identiﬁed in the CF lung [8–10],
indicating that the microbiome ecology in these patients is
more complex than previously thought, which lead to the
concept that CF is a polymicrobial infectious disease [11].
This review focuses on the different technologies used to
identify and to detect bacteria in CF sputum samples (Fig. 1),
including the current phenotypic methods and the recent
molecular tools that have enabled: (i) the correct identiﬁca-
tion of misidentiﬁed bacteria; (ii) the discovery of new patho-
gens; (iii) the better characterization of the main pathogens;
and ﬁnally (iv) an assessment of the complex microbial diver-
sity in CF respiratory tracts using novel culture-independent
approaches.
Conventional and Phenotypic Identiﬁcation
The classical identiﬁcation of bacteria isolated from respira-
tory samples recovered from CF patients is based mainly on
different morphologic and metabolic characters, including
Gram, growth at different temperature, enzyme activity (e.g.
catalase, oxidase, lipase, phosphatase, etc.), carbon and nitro-
gen assimilation with different sugars and amino acid sub-
strates, and antibiotic susceptibility proﬁles. Many of these
characteristics can be tested simultaneously with commercial
kits [e.g. the API (bioMe´rieux, Marcy l’Etoile, France) and
RapID (Remel, Lenexa, KA, USA) systems] and automated
apparatuses such as VITEK (bioMe´rieux), MicroScan-Walk-
Away (Dade Behring Inc.,. West Sacramento, CA, USA) and
Phoenix (Becton-Dickinson, Becton-Dickinson Biosciences,
Franklin Lakes, NJ, USA) (Fig. 1). The ﬁnal identiﬁcation,
which takes between 6 and 48 h (depending on bacterial spe-
cies) after bacterial growth, is given using automated algo-
rithm analysis. This type of identiﬁcation can be performed
only on pure, isolated bacteria (Fig. 1). The agar plates used
are adapted to isolate the main CF pathogens and usually
include ﬁve agar plates, for Gram-positive bacteria, Gram-
negative bacteria, fastidious bacteria and Mycobacterium spp.,
and B. cepacia complex-selective media [8]. Culture methods
are useful for isolation of bacteria and are the ﬁrst step for
identiﬁcation and antibiotic susceptibility testing. However,
many problems can arise from this procedure (Table 1).
First, the oropharyngeal ﬂora and fungi can be cultured, aside
from the pathogens, on the same media, making the isolation
and/or detection of pathogenic bacteria in polymicrobial
sputum more difﬁcult [2]. In addition, in selective media (e.g.
B. cepacia complex agar plates), other emerging bacteria,
including S. maltophilia, A. xylosoxidans, I. limosus, and Herbas-
pirillum spp., can grow and lead to misidentiﬁcation [12–15].
Conversely, many unculturable pathogens and anaerobes
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could be missed on these plates and thus not be detected,
leading to a permanent requirement to develop new media.
It is also known that mucoid P. aeruginosa can invade the agar
plates, obscuring the presence of other bacteria in the same
plate, or it can simply produce substances that inhibit their
growth [16]. Moreover, misidentiﬁcation of bacteria using
the standard phenotypic procedures is increasingly reported
in isolates recovered from CF patients.
Unusual [17] and misidentiﬁed [18–24] bacteria are mainly
documented in the context of CF as a result of: (i) appropri-
ate ecology in the CF lung that supports the growth of
a wide variety of bacteria rarely seen in humans [17];
(ii) long-term airway colonization by some bacteria leading
to phenotypic modiﬁcations as described, for example, in
hypermutable [25,26] and mucoid variants of P. aeruginosa
[27] and also in small-colony variants of several pathogens
(e.g. S. aureus [28], S. maltophilia [29] and P. aeruginosa [30]);
(iii) taxonomic changes concerning some bacteria and the
description of new genera and/or species that are not
included in the database of automated phenotypic identiﬁca-
tion systems [31]; (iv) the recent development of molecular
identiﬁcation methods with superior performance compared
to that of commercial devices and biochemical testing
[32,33]; and (v) some species that are closely related and
have similar phenotypes that make accurate laboratory
identiﬁcation challenging [4].
Misidentiﬁcation of the bacteria in sputa from CF patients
remains problematic, especially of nonfermenting Gram-nega-
tive bacilli. Currently, differentiation of Pandoraea spp., Ralsto-
nia spp. and Burkholderia spp. from each other using
phenotypic tests can be difﬁcult and misleading [2]. Similarly,
confusion of P. aeruginosa with A. xylosoxidans or S. maltophilia
has been recently described [23,34]. Indeed, several highly
transmissible bacteria, such as B. cepacia and P. aeruginosa,
may be misidentiﬁed, and this could delay the therapeutic
management and infection control recommendations in CF
centres [33,35]. Many studies amply illustrate this problem
with high rates of isolated bacteria with incorrect or impos-
sible identiﬁcation [36]. Indeed, this problem is described in
the literature for P. aeruginosa and B. cepacia [2,14,18,23] and
was also encountered in our previous study where we dem-
onstrated that such misidentiﬁcations were also made of
other common bacteria, including S. aureus and S. pneumoniae
[8]. It has been reported, for example, that only 57% of non-
mucoid strains and 40% of mucoid strains of P. aeruginosa
are correctly identiﬁed with the MicroScan Autoscan auto-
mated system, and that extending the incubation to 48 h
improves identiﬁcation [20]. As with mucoid P. aeruginosa
strains, the identiﬁcation of B. cepacia is difﬁcult, and errors
of identiﬁcation are numerous (e.g. of phenotypically homo-
geneous bacteria of the genera Burkholderia, Alcaligenes,
Ralstonia, Stenotrophomonas and Pandoraea [2,14,18]). Con-
versely, bacteria of the genus Alcaligenes, Ralstonia pickettii or
S. maltophilia can be inaccurately identiﬁed as B. cepacia [14].
Moreover, Segniliparus rugosus can be confused with rapidly
growing members of the genus Mycobacterium because of its
rapid growth on culture media designed for mycobacteria
[37]. Interestingly, in a recent multicentre quality assurance
trial of identiﬁcation of CF isolates conducted in 18 Euro-
pean countries, common and emerging CF pathogens were
also misclassiﬁed by many participant laboratories or were
not detected [38].
Finally, for certain bacteria, correct phenotypic identiﬁca-
tion is impossible because they are newly-discovered bacteria
whose phenotypic proﬁles do not exist in the commercial
identiﬁcation system databases (API, Vitek 2). Over the last
10 years, recent taxonomic studies (beneﬁtting from molecu-
lar approaches) have resulted in the description of an
increasing number of new genera and/or species [31]. This is
the case for I. limosus, which is isolated from sputum and
mainly reported in CF patients [17,39–42]. The majority
of the isolates were mucoid, grew on selective B. cepacia
agar, were identiﬁed with API 20 NE as either Sphingomonas
paucimobilis or Agrobacterium radiobacter, and were suscepti-
TABLE 1. Advantages and drawbacks of different techniques used for identiﬁcation and/or detection of bacteria in cystic
ﬁbrosis patients
Tools Advantages Drawbacks
Culture and classical phenotypic identiﬁcation Enable bacterial isolation and antibiotic susceptibility
testing
Missing bacteria (unculturable and/or bacteria missed in
polymicrobial ﬂora)
Misidentiﬁcation.
Molecular means for bacterial identiﬁcation (isolates)
and/or bacterial detection (isolates and sputa)
Correct identiﬁcation of some bacterial genera
and/or species
Missing bacteria.
Misidentiﬁcation in some cases due to lack of
discriminatory power.
No antibiotic susceptibility testing
Molecular means evaluating the biodiversity (sputa) More exhaustive to detect and to evaluate the
complex ﬂora present
No isolated bacteria.
No antibiotic susceptibility results
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ble only to imipenem, ciproﬂoxacin and rifampicin [13,17,
39,40], suggesting that this bacterium is a multiresistant
emerging bacterium in CF patients.
It is interesting to note that many other promising pheno-
typic strategies for the identiﬁcation of bacteria have been
recently applied to resolve the problem of misidentiﬁcation,
including the use of Fourier transform infrared spectroscopy
[43] and matrix-assisted laser desorption/ionization time-
of-ﬂight mass spectrometry (MALDI-TOF MS) [44–46] (Fig. 1).
MALDI-TOF MS for CF Bacterial
Identiﬁcation
This low-cost technique, which is based on protein ﬁnger-
print proﬁling of intact bacterial cells, has already been
applied to identify bacteria recovered from CF patients. It
allows rapid identiﬁcation with a high degree of reliability
and strong potential for correct identiﬁcation, as well as the
possibility of continuous system updating by enlarging the
database with information for a wider range of new bacterial
species and isolates. MALDI-TOF MS has been used success-
fully to characterize nonfermenting isolates of Gram-negative
bacilli from CF patients after engineering the database with a
set of reference strains [44]. Moreover, two other studies
have also demonstrated that B. cepacia complex species, the
more frequently misidentiﬁed CF pathogens, can be identiﬁed
accurately using this methodology [45,46], which is essential
for the timely management of CF patients. More recently,
Seng et al. have described the successful use of MS in the
routine clinical microbiology laboratory [47]. This successful
advance in the application of MALDI-TOF MS for bacterial
identiﬁcation makes it possible, in the near future, for it to
be used also for the routine identiﬁcation of CF pathogens.
Molecular Means for the Correct
Identiﬁcation of Misidentiﬁed Bacteria
Although conventional phenotypic tests fail to produce accu-
rate results [32,33], molecular methods such as PCR fol-
lowed by sequencing (Fig. 1) offer an established, powerful
and reliable option for the correct identiﬁcation of bacteria
(Table 1), especially nonfermenting Gram-negative bacilli
[13,36,48–56].
Accurate identiﬁcation of bacteria is important for both
the epidemiology and the clinical implications of emerging
pathogens in CF patients. For example, correct identiﬁcation
of genomovars within the B. cepacia complex is crucial
because the presence of certain genomovars in CF patients
may be hazardous. Indeed, B. multivorans (genomovar II) and
B. cenocepacia (genomovar III) are the most virulent and
transmissible species [57] associated with a severe decline in
lung function and increased mortality rates. Moreover, lung
transplantation is often avoided in the case of genomovar
II- or III-infected CF patients with the aim of controlling
patient-to-patient transmission [57].
Moreover, the introduction of molecular techniques, espe-
cially 16S rRNA gene ampliﬁcation and sequencing, for the
identiﬁcation of misidentiﬁed or unidentiﬁed bacteria by tra-
ditional methods has revolutionized our current knowledge
with the description of many emerging and multidrug-resis-
tant bacteria that can be found in CF patients, as summarized
in Table 2 [15,17,23,36,37,54,56,58–72].
Other novel molecular approaches have also been devel-
oped recently for rapid and accurate identiﬁcation of bacteria
in CF patients (Fig. 1). Some of these assays target a speciﬁc
bacterial species using real-time PCR (RT-PCR) for identiﬁca-
tion of isolates, e.g. of the B. cepacia complex by multiplex
recA and 16S rRNA gene RT-PCR [73], of I. limosus by 16S
rRNA gene RT-PCR [13] and of P. aeruginosa by duplex ecfX
and the gyrB gene RT-PCR [34]. Fluorescence in situ
hybridization has also been used for A. xylosoxidans, Alcalige-
nes faecalis [74] and B. cepacia complex identiﬁcation [75].
These different assays are both practical and appropriate for
a modern clinical microbiology laboratory. Additionally, more
recent and sophisticated approaches have been developed
for the identiﬁcation of bacteria (i.e. nonfermenting
Gram-negative rods) including capillary electrophoresis-
single-strand conformation polymorphism analysis [76] and
ribosomal intergenic spacer analysis-high performance liquid
chromatography [77].
Although 16S rRNA gene ampliﬁcation and sequencing
remains the universal reference standard technique for bacte-
rial identiﬁcation, its discriminatory ability for the identiﬁca-
tion of bacteria at the species level is, in some cases, limited
and species-dependent (Table 1). In this situation, other
genes should be analyzed for bacterial species or subspecies
identiﬁcation. This is the case for B. cepacia complex,
Burkholderia gladioli, Ralstonia spp., Pandoraea spp. and
Mycobacterium spp., for which other genes such as recA, 23S
rRNA, gyrB and rpoB are more variable in sequence and have
a higher discriminatory power for identiﬁcation [78–81].
Moreover, for the B. cepacia complex, sequencing of several
genes by using the multilocus sequence typing method and/or
the polyphasic taxonomic approach are sometimes needed to
resolve the difﬁculty of identiﬁcation of strains at the subspe-
cies level or for genotyping [57,78,82]. Typing of bacterial
strains is also required to understand the epidemiology,
routes or sources of infections, aiming to optimize healthcare
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TABLE 2. Bacterial species described in the context of cystic ﬁbrosis
Bacterial species References Bacterial species References
Abiotrophia defectiva [8,10,89] Moraxella catarrhalis [8]
Acetobacter indonesiensis [58] Moraxella osloensis [17]
Achromobacter ruhlandi [10] Mycobacterium abscessus [7,10]
Achromobacter xylosoxidans [8,10] Mycobacterium avium [7]
Acinetobacter baumannii [4] Mycobacterium simiae [7]
Acinetobacter sp. [17] Neisseria cinerea [10]
Actinomyces graeventzii [10] Neisseria sp. [8,87]
Actinomyces naeslundii [70] Neisseria subﬂava [10]
Actinomyces odontolyticus [10,70] Neissieria ﬂava [70]
Actinomyces sp. [8,87] Neissieria mucosa [70]
Actinomyces viscosus [70] Nocardia asiatica [62]
Advenella incenata [59] Nocardia asteroides [63]
Agrobacterium radiobacter [36] Nocardia elegans [62]
Alcaligenes faecalis [74] Nocardia farcinica [64]
Atopobium parvulum [70] Nocardia transvalensis [62]
Atopostipes suicloacalis [10] Novosphingobium sp. [10]
Bacillus licheniformus [70] Ochrobactrum anthropi [36,56]
Bacillus pumilis [70] Paenibacillus cineris [69]
Bacteroides fragilis [89] Pandoraea apista [4]
Bdellovibrio sp. [10] Pandoraea norimbergensis [4]
Bergeyella sp. [8,87] Pandoraea pnomenusa [4]
Biﬁdobacterium longum [70] Pandoraea pulmonicola [4]
Biﬁdobacterium sp. [87] Pandoraea sputorum [4]
Bordetella avium [60] Pantoea agglomerans [23]
Bordetella bronchiseptica/parapertussis [61] Peptostreptococcus micros [70]
Bordetella hinzii [17] Peptostreptococcus prevotii [70]
Bordetella petrii [60] Peptostreptococcus sp. [8,87]
Bordetella sp. [10] Porphyromonas sp. [8,10]
Brevundimonas diminuta [32,56] Prevotella corporis [70]
Bulleidia moorei [70] Prevotella denticola [8,10]
Burkholderia ambifaria [2,57] Prevotella disiens [70]
Burkholderia anthina [2,57] Prevotella melaninogenica [8,10,70]
Burkholderia arboris [78] Prevotella oris [8,10,89]
Burkholderia cenocepacia [2,4,57,78] Prevotella pallens [10,70]
Burkholderia cepacia [2,57] Prevotella salivae [8,70]
Burkholderia contaminans [78,82] Prevotella sp. [8,10,87]
Burkholderia dolosa [4,57] Propionibacterium acnes [10,70]
Burkholderia fungorum [17] Pseudomanas ﬂuorescens [71]
Burkholderia gladioli [79] Pseudomonas aeruginosa [8,10,87,89]
Burkholderia lata [82] Pseudomonas alcaligenes [36]
Burkholderia multivorans [2,4,8,57] Pseudomonas brassicacearum [36]
Burkholderia pseudomallei [72] Pseudomonas mendocina [23]
Burkholderia pyrrocinia [2,57] Pseudomonas putida [71]
Burkholderia stabilis [2,57] Pseudomonas sacchoraphila [10]
Burkholderia vietnamiensis [2,4,57] Pseudomonas sp. [88]
Campylobacter concisus [10] Pseudomonas stutzeri [71]
Campylobacter sp. [87] Pseudomonas synxantha [36]
Capnocytophaga infantium [10] Ralstonia mannitolilytica [51]
Capnocytophaga sp. [8] Ralstonia pickettii [51]
Carnobacterium sp. [8] Ralstonia basilensis [51]
Caulobacter sp. [10] Ralstonia gilardii [4,51]
Chryseobacterium gleum [65] Ralstonia insidiosa [4,51]
Chryseobacterium indologenes [65] Ralstonia metallidurans [51]
Chryseobacterium meningosepticum [65] Ralstonia paucula [4,51]
Chryseobacterium sp. [17,36] Ralstonia respiraculi [4,51]
Citrobacter murliniae [89] Ralstonia taiwanensis [4,51]
Clostridium bartlettii [10] Rhizobium radiobacter [17,23]
Clostridium hastiforme [70] Rhizobium sp. [10]
Comamonas testosteroni [10,17] Rickettsiales sp. [10]
Cupriavidus respiraculi [23] Rothia dentocariosa [70,87]
Dialister pneumosintes [8] Rothia mucilaginosa [8,70]
Dolosigranulum pigrum [8,9] Sarcina ventriculi [89]
Eikenella corrodens [8] Segniliparus rugosus [37]
Escherichia coli [8,10,70,87] Selenomonas infelix [8]
Fusobacterium gonidiaformans [89] Selenomonas noxia [8]
Fusobacterium nucleatum [10,70] Selenomonas sp. [8]
Fusobacterium sp. [10,87] Serratia marcescens [8]
Gemella bergeri [10] Sphingomonas paucimobilis [36]
Gemella haemolysans [8] Staphylococcus aureus [8,10,87]
Gemella morbillorum [8] Staphylococcus epidermidis [70]
Gemella sanguinis [8,10,70] Staphylococcus hominis [70]
Granulicatella adiacens [8,10] Staphylococcus pasteuri [70]
Granulicatella elegans [10] Staphylococcus saccharolyticus [70]
Granulicatella paradiacens [8] Stenotrophomonas maltophilia [8,10,89]
Haemophilus inﬂuenzae [8,10,87] Stomatococcus mucilaginosus [87]
Herbaspirillum frisingense [15] Streptococcus agalactiae [66]
Herbaspirillum huttiense [15] Streptococcus anginosus [8,70,95]
Herbaspirillum putei [15] Streptococcus constellatus [8,70,88,95]
Herbaspirillum seropedicae [15] Streptococcus cristatus [8,10,70]
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services and to prevent transmission between patients. It
can also provide an idea of bacterial population dynamics.
Epidemic emerging strains in CF patients have been compre-
hensively reported, especially for the principal pathogens,
including B. cepacia complex [57], P. aeruginosa [83] and meth-
icillin-resistant S. aureus [84,85]. The various genotyping
methods that can be used have been reviewed recently [86].
However, although these techniques have been used for the
correct identiﬁcation of bacteria, they do not allow evaluation
of the actual bacterial diversity, and so many bacterial species
can be missed (Table 1).
Molecular Techniques for the Evaluation of
Bacterial Diversity
Although routine culture methods yield limited microbiolog-
ical information for CF sputa [16], current knowledge indi-
cates that CF respiratory infections must be considered as
polymicrobial infections [11]. Indeed, culture-independent
studies using molecular tools (including 16S rRNA gene clo-
nal library sequencing [8,10], 16S rRNA gene pyrosequenc-
ing [9], temporal temperature gradient gel electrophoresis
16S rRNA gene PCR [87] and 16S rRNA gene terminal
restriction fragment length polymorphism (T-RFLP) proﬁling
[88–91]) have allowed a more precise evaluation of the
microbial diversity in the lungs of CF patients (Table 1).
The strength of these different analyses lies in the fact that
they can be performed directly from clinical samples with-
out any need for culturing (Fig. 1). The results obtained
demonstrate the existence of a large known and unknown
cadre of bacterial species residing in CF lungs with a high
prevalence of anaerobic bacteria and oropharyngeal ﬂora
(Table 2). Different approaches applying these culture-inde-
pendent methods have been extensively used to study the
microbial communities, including Sanger clone sequencing
[8,10] and pyrosequencing [9]. In our 16S rRNA gene
ampliﬁcation and cloning study, 760 clones were obtained
from 25 CF patients (children and adults), which resulted in
the identiﬁcation of 53 different bacterial species (Table 2)
[8].
The mean number of bacterial species per sputum was
7.2 ± 3.9 (range 1–14). Interestingly, the mean number of
detected bacterial species increased when ribosomal genes
from more clones were sequenced, indicating the complexity
of microbial communities in the samples from these patients
[8]. Of the 53 bacterial species detected, 16 (30%) were
anaerobic bacteria of different genera, such as Prevotella,
Veillonella, Porphyromonas and Selenomonas (Table 2) [8].
Finally, many new or emerging bacterial species were also
detected, including Dolosigranulum pigrum, Dialister pneumosin-
tes, Granulicatella adiacens and Rothia mucilaginosa (Table 2)
[8]. In a similar study, more clones (>6000) were screened
from 28 CF children to identify 65 bacterial species (Table 2)
[10]. The mean number of bacterial species per sputum was
5.3 ± 4.9 (range 1–21), and the percentage of anaerobes ran-
ged from 27% to 93% of the clones examined.
Moreover, candidate pathogens such as Prevotella denticola,
Lysobacter enzymogenes and members of the Rickettsiales were
detected [10]. More recently, Armougom et al. described the
use of pyrosequencing after 16S rRNA gene ampliﬁcation to
analyze the sputum sample of a CF child [9]. Although the
TABLE 2. (Continued)
Bacterial species References Bacterial species References
Herbaspirillum sp. [17] Streptococcus genomosp. [8]
Inquilinus limosus [10,13] Streptococcus gordonii [8,10]
Johnsonella sp. [10] Streptococcus iniae [8]
Kingella denitriﬁcans [8] Streptococcus intermedius [70,95]
Kingella oralis [8] Streptococcus milleri [10,67]
Klebsiella pneumoniae [10] Streptococcus mitis [8,10,70]
Lachnospiraceae genomosp. [8] Streptococcus oralis [70]
Lactobacillus casei [10,70] Streptococcus parasanguis [8,10,70]
Lactobacillus delbruekii [8] Streptococcus peroris [10]
Lactobacillus fermentum [10] Streptococcus pneumoniae [8]
Lactobacillus salivarius [70] Streptococcus salivarius [8,70]
Lactobacillus sp. [87,88] Streptococcus sanguinis [8,10,70]
Lautropia mirabilis [68] Streptococcus sp. [8,87]
Leptotrichia sp. [89] Streptococcus thermophilus [70]
Leptotrichia wadeii [10] Tannerella forsythensis [8]
Lysobacter enzymogenes [10] Veillonella atypica [8,10,70]
Methylobacterium asaccharovorans [10] Veillonella dispar [10,70]
Methylobacterium sp. [10] Veillonella ratti [10]
Micrococcus luteus [70] Veillonella sp. [8,87]
Mogibacterium timidum [10] Xanthomonas sp. [17]
The references were chosen according to the ﬁrst description of the bacterial species using either culture-dependant or culture-independent molecular methods, except for
some classical pathogens where a review has been selected.
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shortness of pyrosequencing reads combined with the weak
nucleotide sequence variability of the 16S rDNA limited the
assembly of full-length 16S rDNA, this technology provides a
more reliable estimate of the relative abundance and species
richness among the bacteria present [9].
Using reverse transcription T-RFLP, as compared to T-
RFLP, Rogers et al. indicated that the majority of bacterial
species detected in CF sputa are metabolically active and
thus may be clinically signiﬁcant and likely to participate in
CF lung infection [88,92]. Moreover, Rogers et al. [93] dem-
onstrated, by a comparison of T-RFLP proﬁles of isolates
from sputum samples and mouthwash samples collected
from the same adult CF patients, that these reported mixed
ﬂorae cannot be a result of contamination of sputum by bac-
teria present in the oral cavity. The microﬂora may play an
indirect role in the outcome of the disease by modulating
gene expression via interspecies communication [94]. More-
over, these complex ﬂorae can enhance or regulate the
expression of the virulence factors and the pathogenicity of
other organisms (e.g. P. aeruginosa), as demonstrated using a
rat lung infection model and genome-wide transcriptional
analysis [94] and, more recently, using a Drosophila model
[95]. In addition, the response of the host’s innate immune
system towards these infections is complex, highlighting the
potential complexity of polymicrobial infections [95]. In
another study, it was shown that bacteria of the Streptococcus
milleri group are detected in many cases, and that these com-
prise the numerically dominant pathogens in 39% of acute
CF pulmonary exacerbations and can establish chronic infec-
tions [91].
Anaerobes, not currently sought using conventional
culture methods, were also detected frequently via these
culture-independent assays [8,10]. However, it is not surpris-
ing to ﬁnd anaerobic bacteria in CF lungs, especially after the
establishment of chronic infection where many bacteria,
including P. aeruginosa and S. aureus, reside in a bioﬁlm under
hypoxic conditions. This concept is in agreement with recent
studies that revealed high numbers of anaerobic bacteria in
CF sputum samples from which facultative anaerobic species
such as P. aeruginosa and S. aureus were also isolated [70,96].
In these same studies, anaerobic bacteria were detected in
much lower numbers in sputa from healthy individuals and
from patients with pulmonary diseases other than CF [70,96].
It is also possible that these anaerobes are more fre-
quently recovered from CF patients because they have been
selected for after recurrent antimicrobial treatments as a
result of being naturally resistant to certain antibiotics such
as aminoglycosides [8]. Thus, the potential contribution of
anaerobes in CF pathology requires more investigation in the
future.
Finally, it is interesting to note that denaturing gradient gel
electrophoresis, a technique used mainly for studying and
screening CFTR mutations [97], has not been speciﬁcally
used to screen bacterial communities in CF samples.
In conclusion, molecular culture-independent methods
have provided an interesting opportunity to discover a large
number of known and unknown bacteria, including anaerobes
and new emerging pathogens, living in microbial communities
in the lower respiratory tracts of CF patients. In the future,
the list of bacteria associated with CF patients will continue
to increase via the use of molecular tools. Further metage-
nomic analysis of CF sputa will also rapidly expand this list,
leading to a more precise knowledge about these complex
niches.
Molecular Characterization of Principal
CF-Associated Bacteria and Whole-genome
Sequencing
Full bacterial genome sequencing represents the most com-
plete and powerful tool to understand the physiopathology
of bacterial infection because it gives global information
about the existing virulence factors, mechanisms of antibiotic
resistance, and the genetic materials of a given bacterium.
Although rapid advances in massive DNA sequencing and
increased numbers of whole-genome sequences are available,
only a few genomes of CF-associated strains have been
sequenced to date. Indeed, only three epidemic strains, of
S. aureus (CF-Marseille) [84], P. aeruginosa (LES) [98] and
B. cenocepacia (J2315) [99], have been sequenced and pub-
lished recently.
Genomic analyses of these isolates revealed the presence
of numerous virulence and drug resistance functions
[84,98,99] and mutated genes [100], reﬂecting the adaptive
way of life of these pathogens in a speciﬁc niche, when
exposed to aggressive and multiple antimicrobial therapies,
and during established chronic infection. The main link found
between these genomes was a high level of lateral gene
transfer compared to non-CF isolates. For example, the
J2315 genome contains 14 additional genomic islands (21% of
the genome) compared to non-CF B. cenocepacia strains
[99]. The functions of these islands appear to lie in the
promotion of survival and pathogenesis in the CF lung [99].
Prophages that play an important role in genomic evolution
of bacteria and genome diversity [101,102] via horizontal
gene transfer were also found in these sequenced strains.
Interestingly, recent studies demonstrate that some antibiot-
ics, especially those frequently used in CF patients (e.g.
ciproﬂoxacin, tobramycin, cotrimoxazole and imipenem), can
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enhance phage mobility [84,103], leading to the frequent
exchange of genetic material and spread of virulence and/or
antibiotic resistance genes among bacterial species. More
recently, metagenomic analysis of DNA virus communities in
the respiratory tract of CF individuals has demonstrated a
higher abundance of phage communities in these patients,
especially Staphylococcus phages, that are associated with
airway pathology [104]. Moreover, prophages were recently
found as critical genomic determinants for competitiveness
of the epidemic strain of P. aeruginosa in a chronic infection
model [98]. According to these data, it is likely that phages
participate in the physiopathology of the disease by rapid
adaptation via lateral gene transfer. More studies are needed
to illustrate the role of bacteriophages and other viruses in
these infections using metagenomic analysis.
Microarray assays were also carried out aiming to charac-
terize CF pathogens, especially P. aeruginosa and S. aureus
isolates. This tool was used to study the regulation of gene
expression concerning virulence factors, antimicrobial resis-
tance and persistence factors during different stress condi-
tions in P. aeruginosa [26,105–112], B. cenocepacia [113] and
S. aureus [84,114], as well as to assess variation in the geno-
mic repertoire of P. aeruginosa strains [115,116]. The results
obtained again indicate an adaptive and defensive response of
these opportunistic bacteria that may contribute to the
morbidity and mortality in CF. More recently, a model for
niche-transcriptional response derived by analyzing gene
expression in different environmental niches via high-through-
put cDNA sequencing, was performed in two B. cenocepacia
isolates (one isolated from a CF patient and another from
agricultural soil) and was informative for understanding the
bacterial response to its ecology [117].
Although these two strains share a 99.8% average nucleo-
tide identity in their conserved genes, many regulatory and
potential virulence factors were over-expressed under condi-
tions mimicking the CF lung compared to those of soil [117].
This may represent speciﬁc adaptations to the niches from
which each strain was isolated [117]. Finally, interactions
between CF-associated bacterial species were also studied
using microarrays [94,118]. Interestingly, one of these analy-
ses demonstrated that microﬂora can modulate gene expres-
sion of other pathogens, such as P. aeruginosa [94], again
emphasizing that very little is known about the complex
microbial infections in CF patients. Both genome sequencing
of other bacterial species and assessment of their transcrip-
tional responses in the CF niche can contribute effectively in
the future to better deﬁne our current understanding of
respiratory infections in CF patients.
Conclusions and Perspectives
Although bacterial infections in CF patients were considered,
in the past, to be a result of only a few pathogens, recent
advances in molecular methods have led to the recognition
of an increasing number of bacteria associated with these
patients. This trend is reliant on a better identiﬁcation of
bacteria or a more exhaustive analysis of sputum samples.
Respiratory specimens
Culture
Bacterial isolates Oro-pharyngeal flora
Classical phenotypic identification
Antimicrobial susceptibility testing
MALDI-TOF MS identification
Good identification
Misidentification or discordance
between phenotypic identification, 
antibiotic susceptibility profile, 
and/or MALDI-TOF MS results
16S rRNA sequencing
and/or real-time PCR
16S rRNA PCR-
cloning-sequencing
Result validation
Patient with clinical
degradation, fever,…
and/or antibiotic treatment
initiation
Result validationResult validation
No clinical
symptom
No further
analysis is needed
FIG. 2. Proposed strategy for the man-
agement and analysis of sputa from cystic
ﬁbrosis patients in clinical microbiology
laboratories. MALDI-TOF MS, matrix-
assisted laser desorption/ionization time-
of-ﬂight mass spectrometry.
816 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 809–820
For these reasons, we are of the opinion that a new strategy
for the correct identiﬁcation of bacterial isolates recovered
from sputum samples (as proposed in Fig. 2) should be
implemented in modern clinical microbiology laboratories.
We consider that MALDI-TOF MS for the routine identiﬁ-
cation of bacteria should be the gold standard in the future
[47]. If an isolated bacterium is not identiﬁed correctly or if
there is discordance between the phenotypic identiﬁcation
and antibiotic susceptibility proﬁle or MALDI-TOF MS
results, the identiﬁcation of the strain by partial 16S rRNA
gene sequencing is warranted, especially for bacteria isolated
on CEPACIA agar. Ampliﬁcation by PCR followed by cloning
must be reserved for speciﬁc cases, especially when it is
impossible to isolate and identify a known pathogen from
sputa among polymicrobial oral ﬂora in a patient with clinical
degradation associated with fever, an inﬂammatory syn-
drome, decreased respiratory function, and/or following lung
transplantation. By contrast, it would be interesting to
develop speciﬁc real-time PCR methods, using probes for
the identiﬁcation of several pathogens (including P. aeruginosa
[119], B. cepacia [73] and I. limosus [13]), in speciﬁc situa-
tions.
Metagenomic studies using high-throughput sequencing
analysis are ongoing in many clinical microbiology areas
[120]. In the future, metagenomic approaches for proﬁling
the CF lung microbiome will help to expand the known
diversity and allow a better understanding of the physiopa-
thology of the complex respiratory infections in the context
of this disease. This was recently demonstrated by an analy-
sis targeting the respiratory DNA virus communities in CF
patients, indicating that the disease state, as a result of the
speciﬁc environment in the CF airway, is deﬁned by metabo-
lism and not by taxonomy [104]. Moreover, monitoring
microbial changes or, more speciﬁcally, gene expression
using oligonucleotide microarrays, can provide a more com-
prehensive view of the biodynamics of micro-organisms
through chronic infections, especially during antimicrobial
therapy [121,122]. Other interesting approaches via DNA
microarrays will be to develop multiple probe arrays able to
detect quickly, accurately and simultaneously, and without
culturing, the best known microbiota in the respiratory tract
of CF patients. In the future, such an assay may take an
important place in the modern clinical microbiology and diag-
nosis laboratories for the timely management of infection in
CF patients.
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